In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £190.00. The company’s shares opened today at ...

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

The Houston Chronicle is pleased to announce that Bao Ong will be our new restaurant critic, effective immediately. A Minnesota native who speaks fluent Vietnamese, Ong began his career in ...

Billy Wagner will be inducted into the Baseball Hall of Fame this summer with a Houston Astros logo on his plaque, the Hall made official Monday. Wagner, the former Houston closer who was elected ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...